歌礼制药有限公司（01672）于2025年12月30日发布翌日披露报表，公告当日根据购回授权进行股份回购。公司已向香港联合交易所有限公司呈交了最新已发行股本变动情况，确认此次回购符合相关上市规则及法例规定。
本次回购数量为100,000股，占公司现有已发行股本约0.0101%，交易价格介于每股港币11.41元至11.64元，总金额约港币1,152,880元。截至公告日，公司已发行股份总数为991,874,320股，另有库藏股7,084,210股，合计998,958,530股。该回购基于2025年5月22日获得的购回授权，授权总额为96,284,628股，截至目前公司合计回购6,186,000股，占授权获批时已发行股本约0.6419%。公告由公司秘书钟明辉签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.